miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 21, 2026

Zacks Industry Outlook Highlights Warner Music, News, IMAX and CuriosityStream

View original at nasdaq.com
Zacks Industry Outlook Highlights Warner Music, News, IMAX and CuriosityStream For Immediate Release Chicago, IL – April 21, 2026 – Today, Zacks Equity Research discussesWarner Music Group WMG, News Corp…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Zacks Film and Television Production and Distribution industry carries a Zacks Industry Rank #159, placing it in the bottom 35% of more than 246 Zacks industries

    60% confidence
  • CuriosityStream plans to launch on up to 20 new platforms

    60% confidence
  • Over the past five years, the industry has traded as high as 3.14X and as low as 1.35X price-to-sales, recording a median of 2.23X

    60% confidence
  • The Zacks Film and Television Production and Distribution industry has increased 18% over the past year compared with the broader sector's 11.6% return

    60% confidence
  • The Zacks Consensus Estimate for CuriosityStream's 2026 earnings is pegged at 4 cents per share

    60% confidence
  • The Zacks Consensus Estimate for News Corp's 2026 earnings has moved south by 2% to 97 cents per share over the past 30 days

    60% confidence
  • The top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1

    60% confidence
  • IMAX has a total addressable market of nearly 4,500 zones

    60% confidence
  • Content costs are skyrocketing as more players enter the field, putting pressure on profitability

    60% confidence
  • The industry is currently trading at 2.73X price-to-sales compared with the S&P 500's 6.03X and the sector's 2.42X

    60% confidence
  • The Zacks Consensus Estimate for WMG's fiscal 2026 earnings has moved north by 0.7% to $1.40 per share over the past 30 days

    60% confidence
  • AI licensing revenues are set to surpass subscription revenues in 2026, with LLM partners expected to more than double

    60% confidence
  • Since April 30, 2025, the industry's earnings estimate for 2026 has moved down 11.2%

    60% confidence
  • News Corp is well-positioned for appreciation in 2026, driven by fundamental catalysts

    60% confidence
  • IMAX targets a record $1.4 billion in global box office for 2026

    60% confidence
  • The Zacks Consensus Estimate for IMAX's 2026 earnings has moved north by 5.7% to $1.67 per share over the past 60 days

    60% confidence
  • Warner Music Group is well-positioned for compelling growth in 2026, backed by strong fundamentals and bold strategic moves

    60% confidence
  • The S&P 500 has risen 42.8% over the past year

    60% confidence
  • IMAX has at least 12 Filmed For IMAX releases planned for 2026

    60% confidence

Data points we hold from this source

S&P 500 · price to sales6.03 multiple
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com